The efficacy and safety of sacubitril/valsartan in heart failure patients: a review
R Zhang, X Sun, Y Li, W He, H Zhu… - Journal of …, 2022 - journals.sagepub.com
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …
[HTML][HTML] Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure
PM da Silva, C Aguiar - Revista Portuguesa de Cardiologia (English Edition …, 2017 - Elsevier
Abstract Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the
neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan …
neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan …
Sacubitril/valsartan for the management of heart failure: a perspective viewpoint on current evidence
Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
E Charuel, T Menini, S Bedhomme… - Pharmacology …, 2021 - Wiley Online Library
This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …
failure, with a focus on important patient outcomes. A systematic review was conducted of …
Cardiovascular outcomes with sacubitril-valsartan in heart failure: emerging clinical data
JJ Cuthbert, P Pellicori, AL Clark - Therapeutics and Clinical Risk …, 2020 - Taylor & Francis
One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
Sacubitril/valsartan: a review in chronic heart failure with reduced ejection fraction
PL McCormack - Drugs, 2016 - Springer
Abstract Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular
sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin …
sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin …
[HTML][HTML] Progress and prospects of Sacubitril/Valsartan: based on heart failure with preserved ejection fraction
R Jia, Y Ji, D Sun - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients
with heart failure. The prevalence of heart failure with normal or near-normal ejection …
with heart failure. The prevalence of heart failure with normal or near-normal ejection …
Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial …
EE Nielsen, JB Feinberg, FL Bu, MH Olsen… - Open …, 2020 - openheart.bmj.com
Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …
Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
H Zhang, T Huang, W Shen, X Xu, P Yang… - ESC Heart …, 2020 - Wiley Online Library
Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …
相关搜索
- heart failure sacubitril valsartan
- meta analysis sacubitril valsartan
- heart failure meta analysis
- efficacy and safety sacubitril valsartan
- heart failure efficacy and safety
- ejection fraction sacubitril valsartan
- efficacy and safety meta analysis
- patient selection sacubitril valsartan
- heart failure ejection fraction
- heart failure patient selection
- adverse effects sacubitril valsartan
- heart failure adverse effects
- perspective viewpoint sacubitril valsartan
- therapeutic puzzle sacubitril valsartan
- important piece sacubitril valsartan
- cardiovascular outcomes sacubitril valsartan